9BioThérapeutiques and TransBIOTech receive a $450,000 Applied Research and Development (ARD) grant to accelerate innovation in oncology
The aim of this multi-year funding is to advance promising cancer therapies by conducting the preclinical toxicity and efficacy studies needed to obtain regulatory approval for clinical trials.
Quebec City, QC, [Date] - 9Bio Thérapeutiques, a biotechnology company specializing in the development of next-generation oncology therapies, today announced a $450,000 grant in partnership with TransBIOTech (Lévis, QC). This Applied Research and Development (ARD) funding is awarded through the College and Community Innovation (CCI) program, administered by the Natural Sciences and Engineering Research Council of Canada (NSERC), in collaboration with the Social Sciences and Humanities Research Council (SSHRC) and the Canadian Institutes of Health Research (CIHR).
This federal investment, spread over three years, will enable 9Bio Thérapeutiques to leverage TransBIOTech's recognized expertise in preclinical research to advance its innovative portfolio of targeted oncology therapies. Complementing a Partenar-IA grant recently awarded by CQDM, this funding will accelerate the development of two therapeutic candidates towards clinical trials, reinforcing Canada's position as a world leader in biotechnology.
TransBIOTech, a College Center for Technology Transfer (CCTT) and not-for-profit organization specializing in applied research including the preclinical development of drug candidates, will contribute its established expertise in the preclinical studies required to satisfy regulatory authorities. These studies include functional tests on the immune system, evaluation of tumor cell destruction, as well as in vivo studies on the pharmacokinetics, efficacy and mechanism of action of candidate therapies. These trials will support regulatory submissions and facilitate progress towards clinical trials.
The therapeutic molecules evaluated in these studies originate from 9Bio's discovery efforts and will be supplied by 9Bio, which will retain full control over their development, regulatory strategy and commercialization. In line with its business model, TransBIOTech will not claim any intellectual property (IP) rights under this agreement.
"The9Bio platform harnesses the power of computational biology to rapidly develop conditionally active therapies. Validating our models and developing our therapies requires cutting-edge technologies and scientific expertise of excellence," said Philipe Gobeil, co-founder, president and chief scientific officer of 9Bio Therapeutics. "This collaboration with TransBIOTech is a key element of our preclinical development strategy and will accelerate our transition to clinical trials."
Fred Couture, Ph.D., Principal Investigator and Head of Pharmaceutical Sciences at TransBIOTech, adds: "We are delighted to support 9Bio's work and contribute to the advancement of innovative therapies. This funding underscores the importance of applied research collaborations in advancing biotechnology innovation and bringing new treatments to patients who do not respond to current therapies or who require more tolerable options. Together with co-investigators Prof. Yvan Boutin and Prof. Marie-EveJanelle, we will use our expertise to accelerate 9Bio's preclinical development."
-30-
About 9BioThérapeutiques
9Bio is a biotechnology company dedicated to the development of innovative oncology therapies. Our AI-guided structural biology platform integrates anatomical and biochemical contexts to design drugs that selectively target tumors. With this approach, we develop drugs specifically directed against tumors, while preserving healthy tissue, improving safety, efficacy and opening the way to previously under-exploited therapeutic modalities. Our pipeline includes three discovery-stage therapies: an antibody-drug conjugate (ADC) targeting tumor cells, an ADC targeting immune cells subverted by tumors, and a modified cytokine. Further information at https://9bio.ca/fr/
About TransBIOTech
TransBIOTech, a Centre collégial de transfert de technologie (CCTT) affiliated with Cégep de Lévis, QC, Canada, is a non-profit organization specializing in biotechnology. Since 1999, TransBIOTech has provided expert support in drug development, offering services in pharmacology, cellular and molecular biology, biochemistry, pharmacokinetics and toxicology. TransBIOTech researchers use their expertise and advanced methodologies to evaluate the mechanism of action, efficacy and safety of therapeutic candidates at different stages of preclinical development.
